23 results
424B5
CKPT
Checkpoint Therapeutics Inc
4 Apr 23
Prospectus supplement for primary offering
6:03am
, that demonstrated that our anti-CAIX antibodies could trigger killing of CAIX-positive human RCC cell lines in tissue culture via ADCC and CDC
424B5
CKPT
Checkpoint Therapeutics Inc
16 Dec 22
Prospectus supplement for primary offering
7:00am
that our anti-CAIX antibodies could trigger killing of CAIX-positive human RCC cell lines in tissue culture via ADCC and CDC. The killing activity
424B5
ircbnq9l
17 Dec 20
Prospectus supplement for primary offering
5:18pm
424B5
49zilwxvue2
21 Sep 20
Prospectus supplement for primary offering
5:02pm
424B5
48doh31n
17 Sep 20
Prospectus supplement for primary offering
5:25pm
424B5
cb0hs22s67vstu84ln3
21 Nov 19
Prospectus supplement for primary offering
8:31am
424B5
nbtno8v7du3sr be057i
19 Nov 19
Prospectus supplement for primary offering
5:26pm
10-K
zyrqe7m3o1waxy5g aqu
17 Mar 17
Annual report
12:00am
10-12G/A
yzha7
19 Aug 16
Registration of securities (amended)
12:00am
10-12G/A
2g3j6ym
29 Jul 16
Registration of securities (amended)
12:00am
10-12G
isd 6zba1mdg2o
11 Jul 16
Registration of securities
12:00am
10-12G/A
ph3 20uoeik0xn1
16 May 16
Registration of securities (amended)
12:00am